News
-
-
COMMUNIQUÉ DE PRESSE
Kaas Wilson Architects Expands Into Southwestern U.S. With Office in Phoenix, Arizona
Kaas Wilson Architects expands its national presence by opening a new office in Phoenix, Arizona, to better serve the southern and western U.S. regions, providing a wider range of services for multi-family housing clients -
COMMUNIQUÉ DE PRESSE
Coaching.com Announces Leadership Transition: Alex Pascal Moves to Executive Chairman, Charlotte Saulny Appointed CEO.
Coaching.com announces strategic leadership transition, with Alex Pascal transitioning to Executive Chairman and Charlotte Saulny becoming CEO. Company positions for future growth -
COMMUNIQUÉ DE PRESSE
Electrovaya and Innovative Rail Technologies Enter into Strategic Supply Agreement for the Supply of Battery Systems for Electric Rail Applications
Electrovaya partners with IRT to supply Infinity battery systems for full electric locomotives, targeting rail applications in industrial operations, ports, short line railroads, defense, and commuter rail -
COMMUNIQUÉ DE PRESSE
Tharimmune Signs Nonbinding Letter of Intent to Merge With Intract Pharma to Create Transformative Oral Biologic Therapeutics Company
Tharimmune, Inc. and Intract Pharma to merge, creating transformative oral biologics company. Merger expected to enhance pipeline growth, innovation, and patient outcomes in the biologics market -
COMMUNIQUÉ DE PRESSE
Moderna Announces First Participant Dosed in Pivotal Phase 3 Trial of Investigational mRNA Norovirus Vaccine, mRNA-1403
Moderna initiates Phase 3 trial for mRNA-1403, an investigational norovirus vaccine, aiming to prevent infection from norovirus. Global recruitment has started -
COMMUNIQUÉ DE PRESSE
Significant Metallurgical Advancement: Moving Toward a New Industry Standard for LiFePO4 Battery Feedstock
St-Georges Metallurgy Corp., a leader in mineral processing technologies, advances lithium processing with a novel one-step LiFePO4 production process. Collaboration with partners aims for cost-effective battery feedstock production and environmental sustainability -
-
-
COMMUNIQUÉ DE PRESSE
NanoViricides, Inc. Has Filed its Annual Report: Broad-spectrum Antiviral NV-387 Progressing to Phase II Clinical Trial - Multiple Indications of NV-387 Include RSV, Influenza, MPOX/Smallpox, COVID
NanoViricides, Inc. reports filing of Annual Report on Form 10-K for fiscal year 2024, financial updates, and plans for Phase II clinical trials of antiviral drug NV-387
